



GI connect

POWERED BY COR2ED

Supported by an Independent Educational Grant from



MEETING SUMMARY

ASCO 2016: JUNE 3RD TO 7TH 2016

WCGIC 2016: JUNE 28TH TO JULY 2ND 2016

BY DR. SHUBHAM PANT – MD ANDERSON CANCER CENTER,
HOUSTON, TEXAS, USA

CANCER OF THE LIVER, SMALL INTESTINE AND PANCREAS TRACT

NETTER 1 TRIAL

Phase III trial: Efficacy and safety of ^{177}Lu -DOTA0-Tyr3-Octreotate (Somatostatin Radionuclide Analogue) in patients with advanced, progressive SSTR positive midgut neuroendocrine tumors

Jonathan R. Strosberg, et al

ESMO 18th World Congress on Gastrointestinal Cancer Barcelona 2016 (WCGIC)

STUDY

- 230 patients grade 1-2 metastatic midgut NETs were randomized to Lutathera, 7.4 GBq every 8 weeks (x4 administrations) vs Octreotide LAR 60 mg every 4 weeks
- **Median PFS:** Not reached for Lutathera and was 8.4 months with control ($p < 0.0001$, HR 0.21)
- **Objective radiographic response rate:** 18% with Lutathera vs. 3% with control ($p = 0.0008$)

ESPAC 4 TRIAL

A multicentre, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma

John P. Neoptolemos, et al

Presented At 2016 ASCO Annual Meeting, Chicago

RESULTS

- Comparison of six cycles of IV gemcitabine alone versus gemcitabine in combination with oral capecitabine
- 60% patients were R1 resections, 80% were node positive and 40% were poorly differentiated
- Median survival for patients treated with gemcitabine and capecitabine was 28.0 months versus 25.5 months for gemcitabine alone
- The estimated 5-year survival rates were 28.8% versus 16.3% in the two groups

**RESORCE: A RANDOMIZED, DOUBLE-
BLIND, PHASE III TRIAL OF REGORAFENIB
IN PATIENTS WITH HEPATOCELLULAR
CARCINOMA PROGRESSING ON
SORAFENIB**

J.Bruix, et al

ESMO 18th World Congress on Gastrointestinal Cancer Barcelona 2016 (WCGIC)

- **Randomized patients with HCC** who had progressed on sorafenib
- The study met its primary endpoint of overall survival
- **Median Overall survival** was 10.6 months for regorafenib versus 7.8 months for placebo ($p < 0.001$)



GI connect

POWERED BY COR2ED

Supported by an Independent Educational Grant from

